Blinatumomab Linked to Higher Costs, Hospitalizations for R/R ALL
The mean total cost of care was $65,437 for blinatumomab, $55,995 for inotuzumab, and $17,520 for other agents.
Leukemia
Study: Nearly One-Third of Children With Hematologic Cancers Develop Cardiotoxicity
All patients with cardiotoxicity recovered within 2 months.
Two-Step Strategy Promising in TKI Dose Reduction in Chronic Myeloid Leukemia
The likelihood of recovery of major molecular response after resuming TKI therapy at reduced doses was 86%.
Bacterial Coinfection Associated With Poor COVID-19 Outcomes in Chronic Lymphocytic Leukemia
Researchers sought to determine the case fatality rate in patients with CLL who were infected with SARS-CoV-2.
AML Treatment Associated With Body Composition Changes in Children
Changes in weight, BMI, and decreased height persist long-term after treatment for AML in pediatric patients.
COVID-19 Vaccines Most Effective in Patients With Myeloma and Gastrointestinal, Lung Cancers
A leukemia or lymphoma diagnosis was tied to lower vaccine effectiveness.
Infection, Tumor Lysis Syndrome Incidence During Initial Days of HMA/Venetoclax Therapy for AML
A retrospective analysis sought to determine the real world outcomes for patients with AML treated with venetoclax and azacitidine or decitabine.
Evusheld Appears Less Effective Against Omicron for Patients With Blood Cancer
A single 150 mg dose of Evusheld demonstrated neutralizing activity against wild-type SARS-CoV-2 but not the omicron variant.
Tibsovo Approval Expanded for Newly Diagnosed IDH1-Mutated AML
The approval was based on data from the phase 3 AGILE trial.
Mitoxantrone and Clofarabine Reinduction for Pediatric Patients With Leukemia
Researchers sought to determine whether a reinduction therapy approach using mitoxantrone with clofarabine would be safe and effective for pediatric patients with leukemia.
- Loading...
Loading...
Next post in Hematologic Cancers
Loading... 
Loading...